Citation: | ZHOU Menglan, ZHANG Lei, YE Wenling, GAO Ruitong. Recurrent Rhabdomyolysis and Renal Insufficiency in a Patient with Hemochromatosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1096-1100. DOI: 10.12290/xhyxzz.2023-0107 |
[1] |
Nakayama M, Kaizu Y, Uesugi N, et al. A case of IgA nephropathy and renal hemosiderosis associated with primary hemochromatosis[J]. Ren Fail, 2008, 30: 813-817. DOI: 10.1080/08860220802249033
|
[2] |
张抒扬. 中国第一批罕见病目录释义[M]. 北京: 人民卫生出版社, 2018: 364-366.
|
[3] |
Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders[J]. Genet Med, 2021, 23: 816-829. DOI: 10.1038/s41436-020-01070-0
|
[4] |
国家卫生健康委员会, 科学技术部, 工业和信息化部, 等. 关于公布第一批罕见病目录的通知[EB/OL]. (2018-06-08)[2023-03-06]. http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
|
[5] |
Yamada K, Taketani T. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency[J]. J Hum Genet, 2019, 64: 73-85. DOI: 10.1038/s10038-018-0527-7
|
[6] |
Ahmed A, de Buitleir C, Elsheik N, et al. Very Long-Chain Acyl-CoA Dehydrogenase Deficiency Presenting as Rhabdomyolysis[J]. Ir Med J, 2022, 115: 565.
|
[7] |
Zhang RN, Li YF, Qiu WJ, et al. Clinical features and mutations in seven Chinese patients with very long chain acyl-CoA dehydrogenase deficiency[J]. World J Pediatr, 2014, 10: 119-125. DOI: 10.1007/s12519-014-0480-2
|
[8] |
张抒扬. 罕见病诊疗指南[M]. 北京: 人民卫生出版社, 2019: 603-608.
|
[9] |
Fatehi F, Okhovat AA, Nilipour Y, et al. Adult-onset very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD)[J]. Eur J Neurol, 2020, 27: 2257-2266. DOI: 10.1111/ene.14402
|
[10] |
Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury[J]. N Engl J Med, 2009, 361: 62-72. DOI: 10.1056/NEJMra0801327
|
[11] |
Boudhabhay I, Poillerat V, Grunenwald A, et al. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis[J]. Kidney Int, 2021, 99: 581-597. DOI: 10.1016/j.kint.2020.09.033
|
[12] |
Neyra JA, Rocha NA, Bhargava R, et al. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report[J]. BMC Nephrol, 2015, 16: 118. DOI: 10.1186/s12882-015-0113-6
|
[13] |
Donati G, Abenavoli C, Vischini G, et al. Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report[J]. Am J Case Rep, 2022, 23: e934220.
|
[14] |
Olynyk JK, Ramm GA. Hemochromatosis[J]. N Engl J Med, 2022, 387: 2159-2170. DOI: 10.1056/NEJMra2119758
|
[15] |
Kane SF, Roberts C, Paulus R. Hereditary Hemochromato-sis: Rapid Evidence Review[J]. Am Fam Physician, 2021, 104: 263-270.
|
[16] |
Okumura A, Kondo K, Hirai C, et al. Nephrogenic diabetes insipidus associated with hemochromatosis[J]. Am J Kidney Dis, 2002, 40: 403-406. DOI: 10.1053/ajkd.2002.34540
|
[17] |
Bonilla SF, Melin-Aldana H, Whitington PF. Relationship of proximal renal tubular dysgenesis and fetal liver injury in neonatal hemochromatosis[J]. Pediatr Res, 2010, 67: 188-193. DOI: 10.1203/PDR.0b013e3181c2df69
|
[18] |
Ozkurt S, Acikalin MF, Temiz G, et al. Renal hemosi-derosis and rapidly progressive glomerulonephritis associated with primary hemochromatosis[J]. Ren Fail, 2014, 36: 814-816. DOI: 10.3109/0886022X.2014.892391
|
[19] |
Hasegawa T, Hori N, Du W. A case of impairment of mitochondrial fatty acid beta-oxidation[J]. Keio J Med, 2002, 51: 100-106.
|
1. |
殷晓玉,蒋诗萌,王军. 辅助技术在智能可穿戴设备中的研究进展. 毛纺科技. 2024(05): 127-133 .
![]() | |
2. |
冯郑文,胡永强,朱宸立,李海瑾,李卉,杜娟. 国外基层老年人辅助技术服务开展现状及对我国的启示. 中华全科医师杂志. 2024(07): 752-757 .
![]() |